The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup
Amanda DeMauro Renaghan, Marlies Ostermann, Claudio Ronco, Karen K. Ballen, Laura Cosmai, Roberta Fenoglio, Matteo Floris, Lui G. Forni, Douglas E. Gladstone, Ilya Glezerman, Stuart L. Goldstein, Shruti Gupta, Sandra M. Herrmann, Edgar A. Jaimes, Kenar D. Jhaveri, Sabine Karam, Abhijat Kitchlu, Heather Landau, Sheron Latcha, David E. Leaf, Paolo Lentini, Jolanta Małyszko, Glen S. Markowitz, Naoka Murakami, Antonello Pani, Mark A. Perazella, Arash Rashidi, Dario Roccatello, Elad Sharon, Ben Sprangers, Vladimı́r Tesař, Verônica T. Costa e Silva, Rimda Wanchoo, Andrew Whitman, Biruh Workeneh, Diana Zepeda‐Orozco, Mitchell H. Rosner
Topics & Concepts
MedicineWorkgroupIntensive care medicineNephrotoxicityKidney diseaseAcute kidney injuryDosingDiseaseChimeric antigen receptorRenal replacement therapyCancerMEDLINETransplantationAcute careKidney transplantationDisease managementClinical trialTargeted therapyRenal functionKidney cancerKidneyHealth careGuidelineQuality of life (healthcare)Drug developmentDrugChemotherapy-induced organ toxicity mitigationRenal cell carcinoma treatmentRenal Diseases and Glomerulopathies